Vanda Pharmaceuticals

Vanda Pharmaceuticals company information, Employees & Contact Information

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.

Company Details

Employees
544
Founded
-
Address
2200 Pennsylvania Avenue Nw,
Phone
3012941900
Email
ko****@****rma.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Washington, DC
Looking for a particular Vanda Pharmaceuticals employee's phone or email?

Vanda Pharmaceuticals Questions

News

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 - Sahm

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 Sahm

Vanda (NASDAQ: VNDA) to release Q3 2025 results Oct 29; call 4:30 PM ET after close - Stock Titan

Vanda (NASDAQ: VNDA) to release Q3 2025 results Oct 29; call 4:30 PM ET after close Stock Titan

Major Regulatory Breakthrough: Vanda Pharmaceuticals Secures FDA Fast-Track Review for Multiple Drugs - Stock Titan

Major Regulatory Breakthrough: Vanda Pharmaceuticals Secures FDA Fast-Track Review for Multiple Drugs Stock Titan

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences - Financial Times

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences Financial Times

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire

Monumental Sports & Entertainment Announces Vanda Pharmaceuticals Inc. as Official Partner and Jersey Patch Partner for the Washington Mystics - Monumental Sports

Monumental Sports & Entertainment Announces Vanda Pharmaceuticals Inc. as Official Partner and Jersey Patch Partner for the Washington Mystics Monumental Sports

Vanda Pharmaceuticals Schedules Q2 Earnings Call: Key Financial Updates Coming July 31 - Stock Titan

Vanda Pharmaceuticals Schedules Q2 Earnings Call: Key Financial Updates Coming July 31 Stock Titan

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration - Finansavisen

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration Finansavisen

Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors - citybiz

Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors citybiz

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference (2024-09-11) - Seeking Alpha

Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference (2024-09-11) Seeking Alpha

Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results - PR Newswire

Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results PR Newswire

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" - PR Newswire

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" PR Newswire

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference - PR Newswire

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference PR Newswire

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S - PR Newswire

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S PR Newswire

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist - PR Newswire

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist PR Newswire

Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference (2024-08-29) - Seeking Alpha

Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference (2024-08-29) Seeking Alpha

Breakthrough Mental Health Drug Seeks FDA Approval for Bipolar and Schizophrenia - Stock Titan

Breakthrough Mental Health Drug Seeks FDA Approval for Bipolar and Schizophrenia Stock Titan

VNDA - Vanda Pharma Latest Stock News & Market Updates - Stock Titan

VNDA - Vanda Pharma Latest Stock News & Market Updates Stock Titan

Vanda Pharma To Present At JMP Securities Conference; Webcast At 12:00 PM ET - RTTNews

Vanda Pharma To Present At JMP Securities Conference; Webcast At 12:00 PM ET RTTNews

Top Vanda Pharmaceuticals Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant